PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

This educational activity is supported by an educational grant from GlaxoSmithKline.

PROGRAM OVERVIEW

Until recently, the only treatment choices for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) included saline irrigation for symptomatic relief, local or oral corticosteroids to keep inflammation under control, and polypectomy through endoscopic sinus surgery. Nasal polyposis is typically present in patients with the highest levels of disease severity, and endoscopic surgery to remove polyps is not the cure one might presume. Nearly 80% of patients who undergo polypectomy experience polyp recurrence within two years and >35% eventually opt for a second surgery. To address this, novel biologics have been and continue to be evaluated for their impact on CRSwNP, giving clinicians treatment options beyond steroids and surgery for their patients with CRSwNP who are struggling to breathe freely. However, these new options necessitate education on clinical trial results for biologic therapy, criteria that should be used when choosing between biologics and surgery, and patient education in regards to treatment with biologics. These topics will be addressed by expert faculty presenters during this initiative.

FACULTY

Tara F. Carr, MD Associate Professor of Medicine Asthma and Airway Disease Research Center University of Arizona Tucson, Arizona

Joseph K. Han, MD, FARS, FAAAAI Professor of Otolaryngology & Head and Neck Surgery Chief, Division of Rhinology & Endoscopic Sinus & Skull Base Surgery Chief, Division of Allergy Eastern Virginia Medical School Norfolk, Virginia

Release date: April 28, 2022 Expiration date: April 28, 2023 Estimated time to complete activity: 60 minutes

TARGET AUDIENCE

This educational activity has been designed for allergists, immunologists, nurse practitioners, and physician assistants who manage patients with CRSwNP.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Review the pathophysiologic/immunogenic molecular drivers of chronic rhinosinusitis (CRS) that lead to the inflammatory endotypes and relevant comorbidities frequently observed in patients with CRSwNP
Discuss the differences between currently approved and emerging biologic treatment options for CRSwNP using data from clinical trials and other analyses
Incorporate an individualized, patient-centric focus based on consensus criteria for patients with CRSwNP when recommending a biologic therapy or endoscopic sinus surgery

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of April 28, 2022 through April 28, 2023 participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education Accreditation Statement Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity: Tara F. Carr, MD Advisor/Consultant: AstraZeneca Advisory Board: Genentech, GlaxoSmithKline Contributor/Reviewer: UpToDate Unbranded Disease State Speaker: Novartis, Regeneron Joseph K. Han, MD, FARS, FAAAAI Consultant: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

New & Emerging Biologic Agents in CRSwNP: Pathophysiology Insights & Patient Selection Criteria